Active Ingredients Screening for Sydney Biopharma Brands
Ultra-fast isolation and bio-fractionation of plant compounds targeting inflammation, metabolic health, and neuroprotection for TGA Listed medicine pipelines.
View Screening Specs »Empowering New South Wales and Australian biopharma, nutraceutical innovators, and complementary medicine manufacturers with high-throughput botanical screening, TGA-aligned assay validations, and scalable contract research.
Bridging traditional botanical pharmacology with Sydney’s cutting-edge biotech infrastructure via verified chromatographic isolation, multi-target receptor bioassays, and high-purity natural compound profiling.
Ultra-fast isolation and bio-fractionation of plant compounds targeting inflammation, metabolic health, and neuroprotection for TGA Listed medicine pipelines.
View Screening Specs »
Comparative multi-batch assessment of active yield variance across distinct harvest seasons, soil regions, and extraction parts to stabilize commercial supply chains.
View Evaluation Details »
GLP-compliant toxicology, acute/sub-chronic tolerance models, and bioavailability tracking built to satisfy both international FDA and Australian therapeutic criteria.
Explore In Vivo Study »
Full development and ICH validation for HPLC-MS, HPTLC fingerprinting, GC, and quantitative testing to secure TGA Certified Listed Medicine release compliance.
Read Method Protocol »Australia’s complementary healthcare sector, centered within the Greater Sydney metropolis and New South Wales bioscience corridors, represents one of the most stringent regulatory environments worldwide under the Therapeutic Goods Administration (TGA).
Sydney serves as the financial and clinical gateway for Oceania’s thriving complementary medicine economy. NSW-based nutraceutical brands, university spin-outs (e.g., Westmead Innovation Quarter, UNSW Sydney, University of Sydney), and OTC leaders demand certified purity. However, local extraction facilities often lack the cost structure and massive chromatographic throughput required to screen thousands of novel fractions.
Worldwide, traditional reverse pharmacology has evolved into modern multi-omics screening. Global healthcare manufacturers are moving past crude extracts toward purified, standardized, bioactive small molecules with validated mechanism of actions (MoA), driven by AI-driven ligand matching and high-resolution mass spectrometry.
A systematic four-phase pathway tailored for Sydney-based brand owners seeking evidence-based claims and rapid therapeutic clearance.
Supercritical CO2, subcritical water extraction, and macroporous resin separation to isolate targeted alkaloids, polyphenols, and polysaccharides.
Enzyme-inhibition assays, cellular inflammation cascades (NF-κB, COX-2), and high-content phenotypic screening in mammalian cell cultures.
ICH Q2(R1) validation using HPLC-DAD, LC-MS/MS, and HPTLC fingerprinting to guarantee absence of heavy metals, pesticides, and residual solvents.
Transfer of analytical chemistry protocols into GMP-compliant pilot batches, toxicology studies, and custom finished dosage design.
| Workflow Parameter | Conventional Sourcing / Domestic Brokers | MedGence (Yineng Pharma) Integrated Pipeline |
|---|---|---|
| Botanical Chemical Verification | Generic Certificate of Analysis (CoA) with nonspecific TLC or UV tests. High risk of species substitution. | Multi-Point Genomic & HPTLC Fingerprinting with verified reference standards and origin tracking. |
| Potency Consistency | Wide batch-to-batch fluctuation due to unmonitored seasonal harvesting and variable crude sources. | Multi-Origin Seasonality Evaluation locking the optimum harvest window for stable target biomarker yield. |
| Safety & Toxicology Data | Literature-based extrapolation without custom in vitro safety or acute toxicity testing. | In Vitro & In Vivo Toxicity Packages (LD50, Ames genotoxicity, 28/90-day sub-chronic models). |
| Sydney & TGA Regulatory Readiness | Often requires re-testing by third-party Sydney laboratories, resulting in costly import bottlenecks. | ICH & TGA Method Validation formats ready for submission to the Australian Register of Therapeutic Goods (ARTG). |
Targeted solutions developed to resolve the primary manufacturing and formulation challenges faced by Sydney companies.
Developing substantiated herbal formulations that align with TGA permitted indications. Our analytical method establishment delivers the quantitative fingerprints required for domestic GMP release specifications.
Sydney's premium skincare brands demand scientifically verified botanicals with anti-photoaging, tyrosinase inhibition, and barrier-repair efficacy backed by in vitro cell-line data.
Extracting high-purity adaptogens, botanical polyphenols, and endurance-enhancing bioactives with strict batch-to-batch guarantees against prohibited alkaloid contaminants.
Explore our complete spectrum of discovery assays, animal efficacy testing, analytical development, and human clinical evaluations.
High-throughput natural product extraction, isolation, and functional target binding assays for pharmaceutical and dietary innovators.
View Service Details »
Quantifying active concentration shifts across varied ecological zones and harvest periods to ensure commercial stability.
View Service Details »
Rigorous rodent in vivo models for bioavailability, organ targeting, systemic clearance, and pre-IND safety documentation.
View Service Details »
Establishing chromatographic fingerprints, HPLC assay validation, and stability-indicating testing under ICH guidelines.
View Service Details »
GCP-compliant human randomized controlled trials (RCT) for supplement substantiation and botanical new drug dossiers.
View Service Details »
Primary and immortalized cell line assays evaluating metabolic regulation, cytoprotection, receptor binding, and pathway modulation.
View Service Details »
Access to over 100,000 characterized natural fractions and compound libraries to accelerate novel drug candidate identification.
View Service Details »
Seamless engineering scale-up from benchtop milligram screening to commercial ton-scale production with full IP protection.
View Service Details »In-depth responses covering regulatory compliance, supply chain logistics, and contract research methodology.